Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAET1G drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAET1G ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Host: HEK293 (Native Glycosylation). |
View RAET1G Products |
| Gene Delivery | RAET1G Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based binding and activation assays. |
View RAET1G Products |
| Benchmark Ab | Anti-RAET1G (Recombinant Biosimilar) Recombinant positive control antibody for assay validation. |
View RAET1G Products |
| Validator | RAET1G siRNA Set For knockdown verification in target-specific validation assays. |
View RAET1G Products |
| Related Target A | NKG2D (KLRK1) The primary functional receptor for RAET1G on NK cells and cytotoxic T cells. |
View NKG2D Products |
| Related Target B | MICA Co-expressed NKG2D ligand; essential for specificity and cross-reactivity screening. |
View MICA Products |
| Related Target C | ULBP2 Highly homologous NKG2D ligand; critical for counter-screening to ensure selectivity. |
View ULBP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation | Human, Cynomolgus, and Mouse RAET1G ortholog proteins available with >95% purity. |
| Subfamily counter-screening (ULBPs/MICs) | Full panel of NKG2D ligands strictly verified by mass spectrometry to guarantee sequence identity. |
| Lack of assay validation controls | Sequence-verified clinical benchmark antibodies included as positive controls. |
| False positives in binding assays | Validated siRNA sets included for functional knockdown and specificity checks. |
Live RAET1G R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RAET1G therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific NK cell engagers (NKCEs) and CAR-NK therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the prevention of RAET1G shedding from tumor cells, a key mechanism of cancer immune evasion. Developing molecules that can selectively bind the membrane-bound form or block metalloproteinase cleavage sites represents the next major frontier in targeting the NKG2D-ligand axis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| NK Cell Engager (NKCE) | Innate Pharma, Affimed | Acute Myeloid Leukemia (AML), Solid Tumors | Dual-affinity validation (Need high-purity RAET1G and NKG2D recombinant proteins) |
| CAR-NK / CAR-T | Nkarta, Celyad Oncology | Colorectal Cancer, Hematological Malignancies | Cell-surface density and target validation (Need Lentivirus for stable cell line construction) |
| Monoclonal Antibodies (Shedding Blockers) | Academic Institutions, Biotech Startups | Advanced Epithelial Ovarian Cancer | Shedding inhibition assays (Need sequence-verified wild-type and cleavage-site mutant proteins) |